Literature DB >> 26669717

QSAR Modeling and Prediction of Drug-Drug Interactions.

Alexey V Zakharov1, Ekaterina V Varlamova2,3, Alexey A Lagunin4,5, Alexander V Dmitriev4, Eugene N Muratov6, Denis Fourches7, Victor E Kuz'min2, Vladimir V Poroikov4, Alexander Tropsha6, Marc C Nicklaus1.   

Abstract

Severe adverse drug reactions (ADRs) are the fourth leading cause of fatality in the U.S. with more than 100,000 deaths per year. As up to 30% of all ADRs are believed to be caused by drug-drug interactions (DDIs), typically mediated by cytochrome P450s, possibilities to predict DDIs from existing knowledge are important. We collected data from public sources on 1485, 2628, 4371, and 27,966 possible DDIs mediated by four cytochrome P450 isoforms 1A2, 2C9, 2D6, and 3A4 for 55, 73, 94, and 237 drugs, respectively. For each of these data sets, we developed and validated QSAR models for the prediction of DDIs. As a unique feature of our approach, the interacting drug pairs were represented as binary chemical mixtures in a 1:1 ratio. We used two types of chemical descriptors: quantitative neighborhoods of atoms (QNA) and simplex descriptors. Radial basis functions with self-consistent regression (RBF-SCR) and random forest (RF) were utilized to build QSAR models predicting the likelihood of DDIs for any pair of drug molecules. Our models showed balanced accuracy of 72-79% for the external test sets with a coverage of 81.36-100% when a conservative threshold for the model's applicability domain was applied. We generated virtually all possible binary combinations of marketed drugs and employed our models to identify drug pairs predicted to be instances of DDI. More than 4500 of these predicted DDIs that were not found in our training sets were confirmed by data from the DrugBank database.

Entities:  

Keywords:  DDI; GUSAR; QNA; QSAR modeling; adverse drug reactions; drug−drug interactions; mixtures; simplex descriptors; toxicity

Mesh:

Substances:

Year:  2016        PMID: 26669717     DOI: 10.1021/acs.molpharmaceut.5b00762

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  20 in total

Review 1.  QSAR without borders.

Authors:  Eugene N Muratov; Jürgen Bajorath; Robert P Sheridan; Igor V Tetko; Dmitry Filimonov; Vladimir Poroikov; Tudor I Oprea; Igor I Baskin; Alexandre Varnek; Adrian Roitberg; Olexandr Isayev; Stefano Curtarolo; Denis Fourches; Yoram Cohen; Alan Aspuru-Guzik; David A Winkler; Dimitris Agrafiotis; Artem Cherkasov; Alexander Tropsha
Journal:  Chem Soc Rev       Date:  2020-05-01       Impact factor: 54.564

Review 2.  Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling.

Authors:  Linlin Zhao; Heather L Ciallella; Lauren M Aleksunes; Hao Zhu
Journal:  Drug Discov Today       Date:  2020-07-11       Impact factor: 7.851

Review 3.  Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.

Authors:  Vertika Gautam; Anand Gaurav; Neeraj Masand; Vannajan Sanghiran Lee; Vaishali M Patil
Journal:  Mol Divers       Date:  2022-07-11       Impact factor: 3.364

4.  Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.

Authors:  Pathima Nusrath Hameed; Karin Verspoor; Snezana Kusljic; Saman Halgamuge
Journal:  BMC Bioinformatics       Date:  2017-03-01       Impact factor: 3.169

5.  Predicting drug-drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge.

Authors:  Takako Takeda; Ming Hao; Tiejun Cheng; Stephen H Bryant; Yanli Wang
Journal:  J Cheminform       Date:  2017-03-07       Impact factor: 5.514

6.  Prediction of Effective Drug Combinations by an Improved Naïve Bayesian Algorithm.

Authors:  Li-Yue Bai; Hao Dai; Qin Xu; Muhammad Junaid; Shao-Liang Peng; Xiaolei Zhu; Yi Xiong; Dong-Qing Wei
Journal:  Int J Mol Sci       Date:  2018-02-05       Impact factor: 5.923

7.  Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.

Authors:  Tesia Bobrowski; Lu Chen; Richard T Eastman; Zina Itkin; Paul Shinn; Catherine Chen; Hui Guo; Wei Zheng; Sam Michael; Anton Simeonov; Matthew D Hall; Alexey V Zakharov; Eugene N Muratov
Journal:  bioRxiv       Date:  2020-06-30

8.  QSAR models of human data can enrich or replace LLNA testing for human skin sensitization.

Authors:  Vinicius M Alves; Stephen J Capuzzi; Eugene Muratov; Rodolpho C Braga; Thomas Thornton; Denis Fourches; Judy Strickland; Nicole Kleinstreuer; Carolina H Andrade; Alexander Tropsha
Journal:  Green Chem       Date:  2016-10-06       Impact factor: 10.182

9.  Comparison of Quantitative and Qualitative (Q)SAR Models Created for the Prediction of Ki and IC50 Values of Antitarget Inhibitors.

Authors:  Alexey A Lagunin; Maria A Romanova; Anton D Zadorozhny; Natalia S Kurilenko; Boris V Shilov; Pavel V Pogodin; Sergey M Ivanov; Dmitry A Filimonov; Vladimir V Poroikov
Journal:  Front Pharmacol       Date:  2018-10-10       Impact factor: 5.810

10.  HIFs: New arginine mimic inhibitors of the Hv1 channel with improved VSD-ligand interactions.

Authors:  Chang Zhao; Liang Hong; Jason D Galpin; Saleh Riahi; Victoria T Lim; Parker D Webster; Douglas J Tobias; Christopher A Ahern; Francesco Tombola
Journal:  J Gen Physiol       Date:  2021-07-06       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.